Introduction In 2020, the British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland, and Public Health England revised post-polypectomy surveillance guidelines. Here, we compare colonoscopy findings and planned surveillance dates at our institution, a tertiary referral centre, with novel recommendations in all patients awaiting surveillance colonoscopy following polypectomy.

Methods All patients awaiting surveillance colonoscopy were collated by endoscopy management. Electronic patient records were accessed to obtain latest colonoscopy findings, histology results and follow-up recommendations. Results and recommendations were compared with the 2020 guidelines and an up-to-date recommendation generated.

Results 330 cases were analysed from 2016–2020. According to new guidance, 74 procedures should continue as planned (22.4%), 221 colonoscopies are not required (66.9%), 7 should be brought forward (2.1%) and 17 pushed back (5.2%). There were 11 cases (3.3%) in which the recommendation was not clear. Reasons included missing data and declined procedures.

Of the colonoscopies to continue as planned, 31 had high risk findings, 12 had low risk findings, 26 were normal and 4 had other findings (eg inflammatory bowel disease). Of the surveillance colonoscopies no longer required, 14 were high risk patients over 75 years, 178 were low risk and 29 were normal. The majority of planned surveillance colonoscopies not needed were previously scheduled for either 3 or 5 year follow up.

Conclusions We present data from a single tertiary referral centre over a four year period. Application of the novel guidance has led to approximately 70% of patients avoiding unnecessary colonoscopies and the associated procedural risks. The cost of a colonoscopy at our centre is £622. We anticipate a potential cost saving of £137,462 in this cohort. The need for, and priority of, investigation, was determined according to the faecal haemoglobin concentration along with assessment for other pre-determined ‘red flag’ symptoms (iron deficiency anaemia, persistent rectal bleeding or daily diarrhoea > 4 weeks, rectal or abdominal mass). Ascertainment of significant colonic disease was determined after 1 year of follow up by linkage of faecal haemoglobin results to local endoscopy, radiology and pathology databases, and finally verified by linkage to the Scottish Cancer Registry.

Results A minimum of 12 month follow up information is available for 3818 patients who submitted a QFIT sample between September and December 2018. A faecal haemoglobin result was available for 3547 patients, and positivity was 25.3%, with 4.4% of results being above the maximum quantifiable value (>400 ug/g stool). 1312 patients had undergone colonoscopy. 54 patients were diagnosed with colorectal cancer within 1 year of having faecal haemoglobin analysed. 51/54 (94.4%) patients had a positive QFIT test, and 53/54 patients (98.1%) had their investigation prioritised based on QFIT result or pre-determined ‘red flag’ symptoms. Only 1/3793 patients developed cancer within one year of an undetectable faecal haemoglobin and in the absence of ‘red flag’ symptoms. Advanced adenomas were found in 9.2% vs 2.1% investigated patients with detectable faecal haemoglobin, and inflammatory bowel disease was diagnosed in 6.2% vs 1.6%. In one sector of the board, introduction of this pathway has reduced demand for ‘direct to test’ colonoscopy by 20%, and demand for all luminal gastroenterology and colorectal surgery outpatient activity by 12.4%.

Conclusion Adopting a pathway incorporating faecal immunochemical testing for haemoglobin in primary care as an adjunct to a formalised clinical assessment can safely determine a patient’s risk of significant colorectal pathology, particularly colorectal cancer, and help prioritise investigation.